[go: up one dir, main page]

CL2010001175A1 - Composicion de vacuna que comprende un antigeno de proteina viral 2 (vp-2) del virus causante de la enfermedad de la bursitis infecciosa (ibdv). - Google Patents

Composicion de vacuna que comprende un antigeno de proteina viral 2 (vp-2) del virus causante de la enfermedad de la bursitis infecciosa (ibdv).

Info

Publication number
CL2010001175A1
CL2010001175A1 CL2010001175A CL2010001175A CL2010001175A1 CL 2010001175 A1 CL2010001175 A1 CL 2010001175A1 CL 2010001175 A CL2010001175 A CL 2010001175A CL 2010001175 A CL2010001175 A CL 2010001175A CL 2010001175 A1 CL2010001175 A1 CL 2010001175A1
Authority
CL
Chile
Prior art keywords
ibdv
vaccine composition
viral protein
protein antigen
virus causing
Prior art date
Application number
CL2010001175A
Other languages
English (en)
Inventor
Mahesh Kumar
Jeffrey Harold Rodenberg
Kalen Cookson
Original Assignee
Zoetis W Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34994418&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2010001175(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zoetis W Llc filed Critical Zoetis W Llc
Publication of CL2010001175A1 publication Critical patent/CL2010001175A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/10011—Birnaviridae
    • C12N2720/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/10011—Birnaviridae
    • C12N2720/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Composición de vacuna que comprende un antígeno de proteinaviral 2 (Vp-2) del virus causante de la enfermedad de la bursitis infecciosa (Ibdv).
CL2010001175A 2004-03-12 2010-10-26 Composicion de vacuna que comprende un antigeno de proteina viral 2 (vp-2) del virus causante de la enfermedad de la bursitis infecciosa (ibdv). CL2010001175A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US55298904P 2004-03-12 2004-03-12

Publications (1)

Publication Number Publication Date
CL2010001175A1 true CL2010001175A1 (es) 2011-04-08

Family

ID=34994418

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2010001175A CL2010001175A1 (es) 2004-03-12 2010-10-26 Composicion de vacuna que comprende un antigeno de proteina viral 2 (vp-2) del virus causante de la enfermedad de la bursitis infecciosa (ibdv).

Country Status (17)

Country Link
US (3) US7338661B2 (es)
EP (2) EP2272949A3 (es)
JP (1) JP4845874B2 (es)
KR (1) KR101172921B1 (es)
CN (1) CN1930284B (es)
AR (1) AR048429A1 (es)
AU (1) AU2005222604B2 (es)
BR (1) BRPI0508660A (es)
CA (1) CA2557844C (es)
CL (1) CL2010001175A1 (es)
CO (1) CO5721019A2 (es)
ES (1) ES2608599T3 (es)
IL (1) IL177903A (es)
MX (1) MXPA06010377A (es)
NZ (1) NZ549687A (es)
WO (1) WO2005089795A2 (es)
ZA (1) ZA200607609B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2608599T3 (es) * 2004-03-12 2017-04-12 Zoetis Services Llc Aislados y vacunas antigénicos del virus de la enfermedad de bursitis Infecciosa
KR101511712B1 (ko) * 2013-04-03 2015-04-13 주식회사 카브 신규 전염성 ｆ낭병 바이러스 ｉｂｄ ｋ7주 및 이를 이용한 전염성 ｆ낭병 백신
KR20210068602A (ko) 2016-06-02 2021-06-09 조에티스 서비시즈 엘엘씨 감염성 기관지염에 대한 백신
CN108126191B (zh) * 2016-12-01 2021-04-06 普莱柯生物工程股份有限公司 一种疫苗组合物及其制备方法和应用
CN108653724B (zh) * 2017-04-01 2020-11-27 普莱柯生物工程股份有限公司 一种用于预防禽减蛋综合征的疫苗组合物、及其制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4530831A (en) * 1982-11-02 1985-07-23 Akzo N.V. Infectious Bursal Disease vaccine
US6471962B1 (en) 1987-06-14 2002-10-29 The University Of Maryland Monoclonal antibodies for infectious bursal disease, vaccines and assays for use therewith
US5192539A (en) 1988-07-21 1993-03-09 Akzo N.V. Infectious bursal disease virus production in continuous cell lines
US5614409A (en) * 1989-05-30 1997-03-25 Commonwealth Scientific And Industrial Research Organisation Production of IBDV VP2 in highly immunogenic form
US5919461A (en) 1989-10-18 1999-07-06 Akzo Nobel N.V. Nonpathogenic infectious bursal disease virus and vaccine
NZ235474A (en) 1989-10-18 1992-12-23 Univ Maryland Virus capable of inducing infectious bursal disease; assay and vaccine
JPH05501064A (ja) * 1990-05-04 1993-03-04 ユニバーシティ　オブ　メリーランド　アット　カレッジ　パーク Ｉｂｄｖタンパク質に関連する特異的ｄｎａ配列並びにベクター、宿主およびワクチン
US5595912A (en) * 1990-05-04 1997-01-21 University Of Maryland College Park Specific DNA and RNA sequences associated with US IBDV variants, vector carrying DNA sequences, host carrying cloned vector, deduced amino acid sequences, vaccine and method of vaccination
IL103939A (en) 1992-12-01 1996-09-12 Abic Ltd An anti-DBI vaccine in birds containing attenuated live DBI virus
US5605792A (en) * 1993-11-04 1997-02-25 The Ohio State University Research Foundation Infectious bursal disease virus VP2 fusion protein expressed by baculovirus, use as diagnostic
US5788970A (en) * 1994-03-29 1998-08-04 The University Of Maryland College Park Chimeric infectious bursal disease virus CDNA clones, expression products and vaccines based thereon
CN1202378A (zh) * 1997-06-02 1998-12-23 财团法人化学及血清疗法研究所 使用细胞系来制备传染性囊病病毒及禽呼肠病毒的方法
US6159472A (en) * 1998-11-16 2000-12-12 Akzo Nobel N.V. Intradermal Avian immunization with inactivated vaccines
US6764684B2 (en) * 2001-09-28 2004-07-20 Zeon Corporation Avian herpesvirus-based recombinant infectious bursal disease vaccine
WO2003074552A1 (en) * 2002-03-01 2003-09-12 Akzo Nobel N.V. An infectious bursal disease virus variant
ATE484579T1 (de) * 2003-03-24 2010-10-15 Intervet Int Bv Infektiöse bursitis-virus mutanten und impfstoffe
ES2608599T3 (es) * 2004-03-12 2017-04-12 Zoetis Services Llc Aislados y vacunas antigénicos del virus de la enfermedad de bursitis Infecciosa

Also Published As

Publication number Publication date
AU2005222604B2 (en) 2011-08-11
NZ549687A (en) 2008-08-29
US8323658B2 (en) 2012-12-04
IL177903A0 (en) 2006-12-31
JP2007528900A (ja) 2007-10-18
CA2557844A1 (en) 2005-09-29
US20110123560A1 (en) 2011-05-26
KR101172921B1 (ko) 2012-08-13
US20050266019A1 (en) 2005-12-01
IL177903A (en) 2015-04-30
CN1930284B (zh) 2010-06-23
EP1722814A2 (en) 2006-11-22
WO2005089795A3 (en) 2006-02-23
KR20060130726A (ko) 2006-12-19
CA2557844C (en) 2016-06-21
AR048429A1 (es) 2006-04-26
CO5721019A2 (es) 2007-01-31
JP4845874B2 (ja) 2011-12-28
ZA200607609B (en) 2008-07-30
US20080193480A1 (en) 2008-08-14
EP1722814B1 (en) 2016-11-09
US7338661B2 (en) 2008-03-04
BRPI0508660A (pt) 2007-08-14
AU2005222604A1 (en) 2005-09-29
EP2272949A2 (en) 2011-01-12
EP2272949A3 (en) 2011-01-19
ES2608599T3 (es) 2017-04-12
CN1930284A (zh) 2007-03-14
WO2005089795A2 (en) 2005-09-29
MXPA06010377A (es) 2007-02-14

Similar Documents

Publication Publication Date Title
EA200900784A1 (ru) Вакцины, включающие антиген из четырех штаммов вируса гриппа
ECSP045300A (es) Antígenos virales
EA200802170A1 (ru) Лиофилизированная композиция терапевтического пептидного антитела
MXPA05009580A (es) Vacuna contra el virus de la influenza.
CY1111552T1 (el) Χρηση hpv16 και hpv18 ως εμβολιο εναντι ενος ή περισσοτερων ογκογονικου hpv τυπου 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68
CY1118492T1 (el) Φαρμακοτεχνικες μορφες εμβολιου norovirus
CY2013036I1 (el) Συνθεσεις εμβολιου κατα της ναϊσσερια, που περιεχουν εναν συνδυασμο αντιγονων
JP2005501532A5 (es)
DE60121136D1 (de) Proteasom-influenzavirus-impfstoffzusammensetzung
BRPI0418317A (pt) vacina de aumento de crescimento à base de epitopo de neutralização
DK1526175T4 (da) Coronavirus, nukleinsyre, protein og fremgangsmåder til generering af vaccine, lægemidler og diagnostik
EA200500584A1 (ru) Нуклеозидные производные для лечения инфекционных заболеваний, вызванных вирусом гепатита c
ATE489967T1 (de) Hcv-vakzin
CL2010001175A1 (es) Composicion de vacuna que comprende un antigeno de proteina viral 2 (vp-2) del virus causante de la enfermedad de la bursitis infecciosa (ibdv).
HUP0302265A2 (hu) Rekombináns Newcastle-betegségvírus nukleoprotein-mutánsa markervakcinaként alkalmazva
DK1516058T3 (da) Rekombinante mæslingevira, som udtrykker epitoper på antigener af RNA-vira, samt anvendelse af de rekombinante vira til fremstilling af vacciner
DK1881845T3 (da) Nipah-virusvacciner
EP1623015A4 (en) HA1 OF THE EQUINE-2 INFLUENZAVIRUS EXPRESSIVE DNA VACCINE
CY1114614T1 (el) Αντιγονα αιμοφιλου ινφλουεντσας και αντιστοιχα dna θραυσματα
ATE555794T1 (de) Heilmittel gegen hepatitis
ATE370745T1 (de) Verbesserte polysaccharid- und glykokonjugat- vakzine
NO20040995L (no) Subenhetsvaksine for smittsom bukspyttkjertel-nekrosevirus
ES2417019T8 (es) Procedimiento de caracterización del virus de la enfermedad de la bursitis infecciosa
EP1399481A4 (en) RECOMBINANT ANTIBODIES AGAINST INFECTIOUS BURSITIS VIRUS (IBDV)
ATE518012T1 (de) Isolate des das reproduktions- und atemwegssyndrom verursachenden schweinevirus und ihre verwendung